News
Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to ...
Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over the past decade.
A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...
A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...
The reduced rate will still be almost 10 times the average monthly out-of-pocket costs paid by commercially insured patients.
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Explore more
Pfizer acquired Seagen in 2023 for $43 billion, and shut down construction on a $350 million manufacturing facility the ...
Pfizer and Bristol Myers Squibb have launched a direct-to-patient program offering their blood thinner Eliquis at a 40% discount for cash-paying patients. The list price for Eliquis (apixaban) is ...
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...
After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...
The move is expected to cause a “near-term stock out of Bicillin L-A,” Pfizer said in its statement, with the drugmaker now allocating “limited quantities of inventory to customers during this period ...
3d
Zacks.com on MSNHow Will Pfizer's Oncology Drugs Perform in Q2 Earnings?PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results